Regulus Therapeutics Inc. (RGLS)
NASDAQ: RGLS · IEX Real-Time Price · USD
2.220
-0.040 (-1.77%)
At close: Apr 24, 2024, 4:00 PM
2.330
+0.110 (4.95%)
After-hours: Apr 24, 2024, 4:21 PM EDT
Regulus Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for RGLS stock have an average target of 7.25, with a low estimate of 3.00 and a high estimate of 11. The average target predicts an increase of 226.58% from the current stock price of 2.22.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 25, 2024.
Analyst Ratings
The average analyst rating for RGLS stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +305.41% | Mar 25, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $12 → $11 | Strong Buy | Maintains | $12 → $11 | +395.50% | Mar 19, 2024 |
| Leerink Partners | Leerink Partners | Buy Initiates $6 | Buy | Initiates | $6 | +170.27% | Mar 18, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +305.41% | Mar 18, 2024 |
| Wells Fargo | Wells Fargo | Hold Maintains $2 → $3 | Hold | Maintains | $2 → $3 | +35.14% | Mar 13, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.52
from -1.58
EPS Next Year
-0.62
from -0.52
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | 121.8M | 243.8M |
| Avg | n/a | n/a | n/a | 118.3M | 236.8M |
| Low | n/a | n/a | n/a | 113.7M | 227.6M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | 106.1% |
| Avg | - | - | - | - | 100.2% |
| Low | - | - | - | - | 92.3% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.44 | -0.49 | -0.58 | 1.32 | 4.01 |
| Avg | -0.52 | -0.62 | -0.66 | 1.29 | 3.90 |
| Low | -0.56 | -0.74 | -0.73 | 1.23 | 3.74 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | 212.1% |
| Avg | - | - | - | - | 203.2% |
| Low | - | - | - | - | 191.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.